Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1990 2
1991 2
1993 3
1994 1
1995 3
1996 2
1997 2
1998 3
2000 6
2001 3
2002 4
2003 6
2004 5
2005 6
2006 3
2007 4
2008 2
2009 3
2010 6
2011 4
2012 4
2013 2
2014 3
2015 6
2016 6
2017 4
2018 5
2019 6
2020 11
2021 9
2022 5
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S. Cross NCP, et al. Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4. Leukemia. 2023. PMID: 37794101 Free PMC article. Review.
From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential assessment of levels of residual disease and investigation of possible reasons for resista …
From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagno …
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A, Alkhateeb H, Gangat N. Tefferi A, et al. Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8. Blood Cancer J. 2023. PMID: 37460550 Free PMC article. Review.
Allogeneic hematopoietic stem cell transplant (AHSCT) offers the possibility of a >30% 3-year survival rate and should be pursued, ideally, while the patient is still in chronic phase disease. The value of pre-transplant bridging chemotherapy is uncertain in MPN-AP whil …
Allogeneic hematopoietic stem cell transplant (AHSCT) offers the possibility of a >30% 3-year survival rate and should be pursued, ideall …
Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L, Akard LP. Caldemeyer L, et al. Leuk Lymphoma. 2016 Dec;57(12):2739-2751. doi: 10.1080/10428194.2016.1198959. Epub 2016 Aug 10. Leuk Lymphoma. 2016. PMID: 27562641 Review.
With BCR-ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib, many patients with chronic myeloid leukemia in chronic phase (CML-CP) can expect to live near-normal life spans. ...In addition, a …
With BCR-ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib, many patien …
Treatment-free remission in chronic myeloid leukemia.
Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ. Molica M, et al. Clin Adv Hematol Oncol. 2019 Dec;17(12):686-696. Clin Adv Hematol Oncol. 2019. PMID: 31851157
Leukemia stem cells that are resistant to TKIs, and that persist despite undetectable BCR/ABL1 transcript levels, likely are responsible for disease relapse after discontinuation. Efforts geared toward better identification of low levels of BCR/ABL1 …
Leukemia stem cells that are resistant to TKIs, and that persist despite undetectable BCR/ABL1 transcript levels, likel …
Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Radich JP, Mauro MJ. Radich JP, et al. Hematol Oncol Clin North Am. 2017 Aug;31(4):577-587. doi: 10.1016/j.hoc.2017.04.006. Hematol Oncol Clin North Am. 2017. PMID: 28673389 Review.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder that accounts for approximately 10% of new cases of leukemia. ...The National Comprehensive Cancer Network and the European Leukemia Net guidelines incorporate frequent molecular monitorin …
Chronic myeloid leukemia (CML) is a myeloproliferative disorder that accounts for approximately 10% of new cases of leukemi …
Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views.
Tromp VNMF, Timmers L, Koningen L, Janssen JJWM, Westerweel PE, Geelen IGP, de Jong J, Beckeringh JJ, Boons CCLM, Hugtenburg JG. Tromp VNMF, et al. Leuk Lymphoma. 2021 Mar;62(3):649-658. doi: 10.1080/10428194.2020.1839655. Epub 2020 Nov 6. Leuk Lymphoma. 2021. PMID: 33153332
Patients with chronic myeloid leukemia (CML) in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment without relapse. ...Patients considered the absence of side effects the most important benefit whereas fear of disease recurrence …
Patients with chronic myeloid leukemia (CML) in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treat …
Management of chronic myeloid leukemia in blast crisis.
Saußele S, Silver RT. Saußele S, et al. Ann Hematol. 2015 Apr;94 Suppl 2:S159-65. doi: 10.1007/s00277-015-2324-0. Epub 2015 Mar 27. Ann Hematol. 2015. PMID: 25814082 Review.
Due to the high efficacy of BCR-ABL tyrosine kinase inhibition (TKI) in chronic phase (CP) chronic myeloid leukemia (CML), the frequency of blast crisis (BC) is greatly reduced compared to the pre-TKI era. However, TKI treatment of BC has only m …
Due to the high efficacy of BCR-ABL tyrosine kinase inhibition (TKI) in chronic phase (CP) chronic myeloid le …
Prospects for achieving treatment-free remission in chronic myeloid leukaemia.
Saglio G, Gale RP. Saglio G, et al. Br J Haematol. 2020 Aug;190(3):318-327. doi: 10.1111/bjh.16506. Epub 2020 Feb 14. Br J Haematol. 2020. PMID: 32057102 Free PMC article. Review.
In addition to the best possible overall survival, discontinuation of the tyrosine kinase-inhibitor (TKI) treatment [treatment free remission (TFR)] without observing a recurrence of the disease has become a major goal of the therapy of chronic myelogenous …
In addition to the best possible overall survival, discontinuation of the tyrosine kinase-inhibitor (TKI) treatment [treatment free remissio …
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.
Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance. Branford S, et al. Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17. Leukemia. 2019. PMID: 31209280 Free PMC article. Review.
Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention strategies. ...BCR-ABL1 mutations are detected in ~50% of TKI resistant patients but are rarel …
Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and …
Clinico-laboratory pertinences and management of relapsed and refractory.
Musteata V. Musteata V. J BUON. 2021 May-Jun;26(3):1165-1168. J BUON. 2021. PMID: 34268985 Free article.
PURPOSE: The purpose of this study was to assess the biological significance of lactate dehydrogenase (LDH), T315I mutation and treatment options in newly diagnosed and relapsed patients with chronic myeloid leukemia (CML). METHODS: Our clinical-analytical and descr …
PURPOSE: The purpose of this study was to assess the biological significance of lactate dehydrogenase (LDH), T315I mutation and treatment op …
128 results